Evans Syndrome: A Comprehensive Disease Characteristics Report

Disease: Evans syndrome MONDO ID: MONDO:0016030 · Orphanet: ORPHA:1959 · Category: Autoimmune cytopenia / immune dysregulation Report type: Literature-based disease knowledge-base entry (no primary datasets provided; all content derived from aggregated disease-level literature and cohort studies).

Summary

Evans syndrome (ES) is a rare autoimmune disorder defined by the concurrent or sequential occurrence of autoimmune hemolytic anemia (AIHA) — proven by a positive direct antiglobulin (Coombs) test with hemolysis — and immune thrombocytopenia (ITP), sometimes accompanied by autoimmune neutropenia. It is a diagnosis of exclusion, established with a complete blood count, blood smear, and Coombs test after secondary causes have been ruled out. The final common effector mechanism is production of warm IgG autoantibodies against erythrocyte antigens and anti-platelet glycoprotein antibodies, leading to Fc-receptor– and complement-mediated destruction of red cells and platelets, predominantly in the spleen.

The central insight consolidated across this investigation is that Evans syndrome is best understood not as an isolated blood disorder but as a phenotype of systemic immune dysregulation. In children especially, ES is frequently the presenting manifestation of an underlying inborn error of immunity (IEI) — with monogenic or immune-dysregulation causes identified in roughly 50–60% of pediatric autoimmune-cytopenia cohorts (ALPS/FAS pathway, CTLA4, LRBA, PIK3CD/APDS, NFKB1, SASH3, partial DiGeorge syndrome). It may also be secondary to systemic lupus erythematosus (SLE), lymphoproliferative disease, or common variable immunodeficiency. ANA positivity in childhood ES is a strong predictor of progression to SLE.

The clinical course is chronic and relapsing with substantial morbidity and mortality. Nationwide registry data give an adult incidence approaching ~1.8 per million person-years and a median survival of ~7 years overall (dramatically worse — ~1.7 years — for secondary ES). Pediatric-onset disease carries ~16% mortality at 15 years, most often from infection or bleeding, with a very high treatment burden. Management escalates from corticosteroids/IVIG (first-line) to rituximab and sirolimus (steroid-sparing second-line), with genotype-directed targeted immunotherapy (abatacept, leniolisib, JAK inhibitors) increasingly important. This report details all 15 disease-characteristic domains, flagging where evidence is robust versus where it is sparse or not applicable.

Key Findings

F001 — Definition: coexistence of AIHA and ITP

Evans syndrome is consistently defined across cohorts as the simultaneous or sequential association of AIHA (positive direct antiglobulin/Coombs test with hemolysis) and ITP. The two events may occur at the same time or one may follow the other. Diagnosis relies on a full blood count/film and a Coombs test, and is a diagnosis of exclusion after secondary causes are ruled out. In the French OBS'CEREVANCE pediatric AIHA cohort (n=265), Evans syndrome was present in 37% of childhood AIHA cases.

"There is a coexistence of Immune thrombocytopenia (ITP) with Autoimmune haemolytic anaemia (AIHA) and both of these events may occur simultaneously or one follows the other." — PMID: 31983745 "Evans' syndrome was diagnosed in 37% of cases." — PMID: 21228033

F002 — Frequently the presenting sign of an inborn error of immunity (IEI)

In a Tampa Bay prospective autoimmune cytopenia (AIC) cohort (n=104), 51% showed evidence of IEI and 26% had monogenic disorders; IEI prevalence was highest in Evans syndrome (61.5%) and AIHA (62.5%). The most common monogenic causes were partial DiGeorge syndrome (pDGS), followed by variants in NFKB1, CTLA4, and FAS. A germline SASH3 nonsense mutation (c.862C>T; p.Arg288Ter) has been identified as a specific monogenic cause. By contrast, an adult chronic ITP/Evans cohort (n=44) screened with an NGS panel of >370 IEI genes found no fully penetrant IEI, though 18.2% carried heterozygous pathogenic IEI variants — establishing that the diagnostic yield of IEI testing is far higher in pediatric than adult-onset disease.

"Among 104 AIC patients, 53 (51%) showed evidence of IEI, including 27 (26%) with monogenic disorders-most commonly partial DiGeorge syndrome (pDGS), followed by variants in NFKB1, CTLA4, and FAS." — PMID: 41560547 "No cases of IEI were identified despite a high representation of subjects with a personal history of autoimmunity" — PMID: 37792884 "identified a germline mutation in SASH3 (c.862C>T;p.Arg288Ter), indicating a recently identified IEI" — PMID: 37646304

F003 — Chronic, relapsing, multisystem course with ~16% pediatric mortality at 15 years

In the French OBS'CEREVANCE cohort of 151 pediatric-onset ES patients with >5 years follow-up (median 11.3 years): at 10 years, ITP and AIHA were in sustained complete remission in 54.5% and 78.4% respectively; by age 20, 74% had ≥1 clinical immunopathological manifestation (lymphoproliferation, dermatological, GI/hepatic, pulmonary). Survival at 15 years was 84% (~16% mortality); death occurred at a median age of 18 years, most often from infection. The number of second-line treatments and severe/recurrent infections were independently associated with mortality. In an earlier cohort (n=156), 5-year ITP and AIHA relapse-free survival were 25% and 61%, and 69% required ≥1 second-line treatment.

"At 10 years, ITP and AIHA were in sustained complete remission in 54.5% and 78.4% of patients, respectively." — PMID: 33440924 "Survival at 15 years after diagnosis was 84%." — PMID: 33440924 "Overall, 69% of children required one or more second-line immune treatments" — PMID: 26484337

F004 — Treatment: corticosteroids/IVIG first-line; rituximab and sirolimus effective second-line

Standard first-line therapy is corticosteroids ± IVIG, but relapse on taper is common. Rituximab (anti-CD20): in a prospective French pediatric AIHA/Evans cohort (n=61), 75% responded and rituximab allowed steroid withdrawal in 72%; 6-year relapse-free survival was 48% (higher in isolated AIHA than in ES, P<0.05). Sirolimus (mTOR inhibitor): in a multicenter prospective trial of 30 refractory AICs, all 12 ALPS children achieved durable complete response and most patients with Evans syndrome/CVID/SLE responded. Genotype-directed targeted agents are emerging (abatacept for CTLA4/LRBA; sirolimus/leniolisib for ALPS/APDS; ruxolitinib/baricitinib). Splenectomy is effective but its benefit is diminished by immunopathological manifestations and carries infection/thrombosis risk.

"Forty-six patients responded (75%) and the 6-year relapse-free survival (RFS) was 48%." — PMID: 28444729 "sirolimus led to CR and durable responses in a majority of children with refractory multilineage autoimmune cytopenias" — PMID: 26504182

F005 — ANA-positive childhood ES is a strong risk factor for progression to SLE

In the OBS'CEREVANCE cohort, ANA were positive in 20% (355/1803) of children with AIC; 22% of ANA-positive patients developed SLE at a median age of 14.5 years. Progression to SLE occurred in 45% of ANA-positive Evans syndrome patients (vs 20% chronic ITP, 19% AIHA); no ANA-negative patient developed SLE. Independent risk factors were age >10 years at AIC diagnosis (RR 3.67, 95% CI 1.18–11.4, P=.024) and ANA titer >1/160 (RR 5.28, 95% CI 1.20–23.17, P=.027).

"20% of chronic immune thrombocytopenic purpura, 19% of autoimmune hemolytic anemia, and 45% of Evans syndrome" — PMID: 38227934

F006 — Very rare, rising incidence; secondary ES has markedly worse survival

Danish nationwide registry data. Adults (n=242, 1977–2017): mean age at diagnosis 58.5 years, 51.2% women, 27.3% secondary; incidence rose to 1.8 per million person-years and prevalence to 21.3 per million persons by 2016. Median survival was 7.2 years overall (primary 10.9 years; secondary only 1.7 years; secondary 5-year survival 38%); leading causes of death were bleeding, infections, and hematological cancer. Children <13 years (n=21): incidence 0.5–1.2 per million person-years; prevalence rose from 6.7 (1990) to 19.3 (2015) per million; hazard ratio for death was 22-fold higher than matched general-population children.

"The annual Evans syndrome incidence and prevalence rose significantly during the study period, to 1.8 per million person-years and 21.3 per million persons, respectively, in 2016." — PMID: 31292991 "The median survival with Evans syndrome was 7.2 years (primary Evans syndrome: 10.9 years; secondary Evans syndrome: 1.7 years)." — PMID: 31292991 "Hazard ratio for death was 22 fold higher for children with ES compared to matched children from general population" — PMID: 32271826

F007 — Mechanism: defective lymphocyte apoptosis / broken tolerance → autoantibody-mediated cytopenias

A large subset of ES — particularly ALPS — results from defective FAS-mediated extrinsic apoptosis of lymphocytes (germline/somatic FAS, FASLG, CASP10), leading to lymphoproliferation, expansion of TCRαβ+ CD4−CD8− double-negative T (DNT) cells, and autoimmune cytopenias. ALPS biomarkers include elevated DNT cells and elevated soluble FAS ligand (sFASL). Other monogenic causes disrupt tolerance at distinct nodes: CTLA4/LRBA (impaired Treg checkpoint), PIK3CD (APDS, PI3K-δ hyperactivation), NFKB1 (haploinsufficiency), and SASH3 (lymphocyte adaptor; germinal-center hypoplasia). The final common step is warm IgG anti-erythrocyte and anti-platelet-glycoprotein autoantibody production causing Fc-receptor/complement-mediated splenic destruction.

"Autoimmune lymphoproliferative syndrome (ALPS) is a disorder of disrupted lymphocyte homeostasis, resulting from mutations in the Fas apoptotic pathway." — PMID: 22157362 "sFASL level can efficiently discriminate patients with ALPS when using the appropriate thresholds" — PMID: 38700373 "LRBA protein deficiency was shown to be responsible for different types of inborn errors of immunity, such as common variable immunodeficiency (CVID) and autoimmune lymphoproliferative syndrome (ALPS)" — PMID: 31432443

F008 — Clinical phenotype and diagnostic laboratory profile

The phenotype combines features of both cytopenias. AIHA component (HP:0004808): pallor (HP:0000980), fatigue (HP:0012378), jaundice (HP:0000952), dark urine, splenomegaly (HP:0001744); labs show positive DAT (warm IgG±C3d — 74% IgG/IgG+C3d in the pediatric cohort), reticulocytosis, elevated LDH and indirect bilirubin, low haptoglobin. ITP component (HP:0001973): petechiae (HP:0000967), purpura/bruising (HP:0000979), mucosal/GI bleeding (HP:0011897). When ES reflects immune dysregulation, organomegaly is prominent — in LRBA deficiency splenomegaly occurred in 93.3% (14/15). Some patients also have neutropenia (HP:0001875), hypogammaglobulinemia (HP:0004313), and recurrent infections (HP:0002719).

"In 74% of cases the direct antiglobulin test was IgG/IgG+C3d." — PMID: 21228033 "Splenomegaly was seen in 93.3% (14/15) of the patients on admission." — PMID: 31432443

F009 — Natural disease in dogs; FAS-pathway (Fas^lpr) mouse model

Natural disease: ES (concurrent immune-mediated hemolytic anemia + immune-mediated thrombocytopenia) is a recognized spontaneous entity in the domestic dog (Canis lupus familiaris, NCBI:txid9615), reported across breeds including Rottweiler, Miniature Schnauzer, and Dachshund; canine cases are DAT-positive, glucocorticoid/immunosuppressant-responsive, and can be complicated by thrombosis and opportunistic infection — paralleling human disease. Model organism: the FAS pathway underlying ALPS-type human ES is modeled by the MRL/lpr (Fas^lpr) and gld (Faslg) mouse, which develop lymphoproliferation, TCRαβ+ DNT-cell accumulation, autoantibodies, and autoimmune cytopenias; leniolisib reduced lymphoproliferation in murine ALPS.

"presumptively diagnosed with Evans' syndrome (ES)" — PMID: 19411652 "Leniolisib reduced lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome" — PMID: 41608120

The 15-Section Disease Characteristics Report

1. Disease Information

Overview. Evans syndrome is a rare, chronic autoimmune disorder characterized by the combination of AIHA and ITP (± autoimmune neutropenia), occurring simultaneously or sequentially (F001). It is a diagnosis of exclusion made after ruling out secondary causes (SLE, lymphoproliferative disease, IEI, drugs, infection).

Key identifiers: | Resource | Identifier | |---|---| | MONDO | MONDO:0016030 | | Orphanet | ORPHA:1959 | | ICD-10 | D69.3 (ITP component) / D59.1 (AIHA component) — no single dedicated code | | ICD-11 | 3B51.0 / 3A20 (component-based) | | MeSH | Anemia, Hemolytic, Autoimmune; Thrombocytopenia (no unique ES MeSH heading) | | OMIM | No single OMIM entry; monogenic causes have their own (e.g., ALPS 601859; CTLA4 haploinsufficiency 616100; APDS 615513) |

Synonyms: Evans-Fisher syndrome; autoimmune hemolytic anemia with immune thrombocytopenia; combined autoimmune hemolytic anemia and thrombocytopenia.

Information source. Evidence in this report derives from aggregated disease-level resources: national prospective cohorts (French OBS'CEREVANCE), nationwide registries (Danish), and case series/reports — not from a single EHR extract.

2. Etiology

Causal factors. ES is heterogeneous. It may be primary (idiopathic) or secondary to another disorder. A dominant paradigm is that ES is often the hematologic expression of an underlying inborn error of immunity (F002, F007). Documented monogenic/genetic causes: FAS, FASLG, CASP10 (ALPS), CTLA4, LRBA (Treg checkpoint defects), PIK3CD (APDS), NFKB1 (haploinsufficiency), SASH3, and partial DiGeorge syndrome (22q11.2 deletion). Secondary causes include SLE, common variable immunodeficiency, and lymphoproliferative disease.

Genetic risk factors. Germline loss-of-function variants in the genes above; somatic FAS variants in ALPS; the 22q11.2 microdeletion (pDGS). ANA positivity marks a susceptibility state for SLE-associated ES (F005).

Environmental risk factors. Age (bimodal: pediatric and older-adult peaks), female sex (adult 51.2% women), family/personal history of autoimmunity. No established toxin, occupational, or dietary cause. Some secondary cases follow infection or lymphoma.

Protective factors. None specifically established. ANA-negativity predicts against SLE progression (F005). No protective genetic alleles are defined for ES.

Gene–environment interactions. In ANA-positive children, age >10 years plus high ANA titer (>1/160) multiplicatively raise SLE risk (F005), illustrating interaction between an autoantibody "environment" and host age/genetic background. Not otherwise well characterized.

3. Phenotypes

Characteristics. Onset spans neonatal to geriatric; pediatric-onset disease is typically chronic and relapsing (F003), adult disease often chronic. Severity is variable to severe (life-threatening anemia or bleeding possible). Progression is episodic/relapsing-remitting. By age 20, 74% of pediatric-onset patients have ≥1 additional immunopathological manifestation (F003).

Quality-of-life impact. High treatment burden, chronic relapses, transfusion dependence in flares, immunosuppression-related infection risk, and cumulative organ involvement substantially impair QoL; formal EQ-5D/SF-36/PROMIS data specific to ES were not identified (knowledge gap).

4. Genetic / Molecular Information

Causal genes (in monogenic/IEI-associated ES): FAS (OMIM 134637), FASLG, CASP10, CTLA4, LRBA, PIK3CD, NFKB1, SASH3; chromosomal 22q11.2 deletion (partial DiGeorge) (F002, F007).

Pathogenic variants. Documented examples include the SASH3 nonsense variant c.862C>T (p.Arg288Ter) (F002). Variant classes span nonsense/frameshift (loss of function; NFKB1, LRBA, SASH3), missense (gain of function in PIK3CD/APDS), and structural (22q11.2 deletion). ALPS may involve somatic FAS variants restricted to DNT cells as well as germline variants. Functional consequences: loss of function (FAS apoptosis, LRBA/CTLA4 checkpoint, NFKB1), gain of function (PIK3CD/PI3K-δ hyperactivation).

Modifier genes. Not formally established for ES; disease expression is modified by the specific IEI genotype and by secondary triggers (SLE, lymphoma).

Epigenetic information. No ES-specific DNA-methylation or histone-modification signature was identified in the literature reviewed (knowledge gap).

Chromosomal abnormalities. 22q11.2 deletion (partial DiGeorge) is the single most common monogenic-level cause in one large pediatric AIC cohort (F002).

5. Environmental Information

Environmental factors. No established chemical, radiation, or occupational cause. Infectious agents may act as triggers in secondary ES, and infections are a leading complication/cause of death, but no single pathogen is causal. Lifestyle factors are not established causes; comorbidities such as diabetes and heavy smoking appear in case reports of thrombotic complications but are not disease causes. ES itself is autoimmune, not infectious or transmissible.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation):

1. A germline (or somatic) genetic lesion in a tolerance/apoptosis gene — e.g., FAS/FASLG/CASP10, CTLA4, LRBA, PIK3CD, NFKB1, SASH3 — leads to defective lymphocyte homeostasis or a broken immune checkpoint (upstream; demonstrated for these IEIs). In primary/idiopathic ES without an identified gene, this step is inferred.
2. Branch A (ALPS-type): defective FAS-mediated extrinsic apoptosis results in failure to delete autoreactive lymphocytes → lymphoproliferation and accumulation of TCRαβ+ CD4−CD8− double-negative T (DNT) cells (demonstrated; DNT cells and elevated soluble FASL are diagnostic biomarkers).
3. Branch B (checkpoint-type): CTLA4/LRBA loss, PI3K-δ hyperactivation (APDS), or NFKB1 haploinsufficiency results in impaired regulatory T-cell function and dysregulated B/T-cell activation.
4. Both branches converge on loss of B-cell tolerance and results in activation of autoreactive B cells / plasma cells.
5. This leads to production of warm IgG autoantibodies against red-cell antigens and anti-platelet glycoprotein (e.g., GPIIb/IIIa) antibodies (demonstrated effector step).
6. Autoantibody opsonization results in Fc-receptor– and complement-mediated phagocytosis/destruction of erythrocytes and platelets, predominantly by splenic macrophages (downstream effector).
7. This leads to the clinical manifestations: hemolytic anemia (pallor, jaundice, reticulocytosis, low haptoglobin, high LDH/bilirubin) and thrombocytopenia (petechiae, purpura, bleeding) (F007, F008).

 Genetic lesion (FAS/CTLA4/LRBA/PIK3CD/NFKB1/SASH3 or unknown)
          │
   ┌──────┴───────────┐
   ▼                   ▼
 Defective FAS       Impaired Treg / checkpoint
 apoptosis (ALPS)    (CTLA4, LRBA, APDS, NFKB1)
   │  DNT-cell         │
   │  expansion        │
   └──────┬────────────┘
          ▼
  Loss of B-cell tolerance → autoreactive plasma cells
          ▼
  Warm IgG anti-RBC + anti-platelet autoantibodies
          ▼
  Fc-receptor / complement-mediated splenic destruction
          ▼
  AIHA + ITP  (Evans syndrome)

Molecular pathways: FAS/FASLG extrinsic apoptosis (caspase-8/10); PI3K-AKT-mTOR (APDS; rationale for sirolimus/leniolisib); CTLA4–CD80/86 costimulation checkpoint; NF-κB signaling. Cellular processes: defective apoptosis, lymphoproliferation, breakdown of self-tolerance, complement activation, macrophage phagocytosis. Immune involvement: combined autoimmunity + immunodeficiency (recurrent infection). GO terms: apoptotic process (GO:0006915), regulation of immune response (GO:0050776), complement activation (GO:0006956), phagocytosis (GO:0006909). Cell types (CL): double-negative T cell, regulatory T cell (CL:0000815), B cell/plasma cell (CL:0000786), macrophage (CL:0000235), erythrocyte (CL:0000232), platelet/thrombocyte (CL:0000233).

7. Anatomical Structures Affected

Organ level. Primary: spleen (UBERON:0002106; principal site of destruction and often enlarged), bone marrow (UBERON:0002371; compensatory hyperplasia), blood (UBERON:0000178). Secondary/associated: lymph nodes (UBERON:0000029; lymphoproliferation), liver (UBERON:0002107; hepatomegaly, associated autoimmune hepatitis), lungs and GI tract in multisystem ES. Body systems: hematopoietic/immune (primary), with cardiovascular (thrombosis risk), hepatic, pulmonary, and GI involvement in immune-dysregulation subtypes.

Tissue/cell level. Targets: erythrocytes (CL:0000232) and platelets (CL:0000233); effectors: splenic macrophages (CL:0000235), dysregulated T cells (including DNT cells) and B cells/plasma cells.

Subcellular level. Death-inducing signaling complex at the plasma membrane (FAS/FADD/caspase); autoantibody targets are red-cell membrane proteins and platelet-surface glycoproteins. GO cellular components: plasma membrane (GO:0005886), death-inducing signaling complex (GO:0031264).

Localization. Systemic; splenic destruction is central. Lateralization not applicable (systemic hematologic disease).

8. Temporal Development

Onset. Bimodal — pediatric (childhood) and older-adult (mean 58.5 years in the Danish adult cohort). Onset pattern is typically subacute to chronic/insidious, though acute severe hemolytic or bleeding crises occur. The two cytopenias may present simultaneously or years apart (F001).

Progression. Relapsing-remitting/episodic, chronic lifelong course (F003). Pediatric 5-year relapse-free survival: ITP 25%, AIHA 61%. At 10 years, sustained CR in 54.5% (ITP) and 78.4% (AIHA). Multisystem immunopathology accrues over time (74% by age 20).

Patterns. Remissions are usually treatment-induced; spontaneous durable remission is uncommon in pediatric-onset disease. Critical windows: early diagnosis of an underlying IEI opens the door to genotype-targeted therapy; monitoring for immunopathological manifestations refines splenectomy risk–benefit.

9. Inheritance and Population

Epidemiology (F006). Adult incidence ~1.8 per million person-years, prevalence ~21.3 per million (Denmark, 2016). Pediatric incidence 0.5–1.2 per million person-years; pediatric prevalence rising (6.7→19.3 per million, 1990→2015). Adult mean age at diagnosis 58.5 years; 51.2% women; 27.3% secondary.

Genetic etiology. Inheritance depends on the underlying IEI: autosomal dominant (ALPS/FAS, CTLA4 haploinsufficiency, NFKB1, PIK3CD GOF), autosomal recessive (LRBA), X-linked (SASH3), or de novo/structural (22q11.2 deletion). Penetrance is incomplete and age-dependent (e.g., CTLA4 haploinsufficiency). Expressivity is variable. Somatic mosaicism occurs in ALPS (somatic FAS variants). Anticipation, founder effects, and consanguinity are not general features of ES, though consanguinity increases recessive-IEI (LRBA) risk. Most "primary" ES has no identified single gene and behaves as a multifactorial/polygenic autoimmune trait.

Population demographics. No strong ethnic predilection established; adult female predominance is modest (~51%). Geographic distribution is worldwide; rising recorded incidence likely reflects better ascertainment.

10. Diagnostics

Clinical/laboratory tests (F008). CBC with blood smear (spherocytes, polychromasia, low platelets); direct antiglobulin (Coombs) test (warm IgG ± C3d; 74% IgG/IgG+C3d); reticulocyte count (elevated); LDH (elevated), indirect/unconjugated bilirubin (elevated), haptoglobin (low); platelet count (low). LOINC-codable analytes: hemoglobin, platelet count, reticulocytes, LDH, bilirubin, haptoglobin, DAT.

Biomarkers. For underlying ALPS: elevated TCRαβ+ DNT cells and soluble FAS ligand (sFASL); also elevated vitamin B12 and IL-10 in ALPS. ANA (SLE risk marker). Immunoglobulin levels (hypogammaglobulinemia in IEI).

Genetic testing. Given the high IEI yield in pediatric ES (F002), NGS gene panels (>370 IEI genes), whole-exome sequencing, and increasingly whole-genome sequencing are recommended, especially in children, early-onset, syndromic, or treatment-refractory cases. Chromosomal microarray/FISH for 22q11.2 deletion (partial DiGeorge). Targeted single-gene testing when a specific IEI is suspected. Adult isolated ES has lower monogenic yield.

Clinical criteria & differential diagnosis. Diagnosis is clinical + laboratory (coexistent AIHA and ITP with positive DAT) after exclusion of: thrombotic thrombocytopenic purpura / thrombotic microangiopathy (check ADAMTS13; <10 IU/dL indicates iTTP), SLE, drug-induced cytopenias, lymphoproliferative disease, DIC, and hemophagocytic syndrome. Microangiopathic hemolysis with schistocytes distinguishes TMA from the warm-antibody hemolysis of ES.

Screening. No population screening. Cascade genetic screening of relatives is appropriate when a monogenic IEI is identified. No newborn screening for ES.

11. Outcome / Prognosis

Survival/mortality (F003, F006). Adult median survival 7.2 years (primary 10.9 years; secondary only 1.7 years, 5-year survival 38%). Pediatric survival at 15 years 84% (~16% mortality), death at median age 18 years; pediatric HR for death 22× the general population. Leading causes of death: infection, bleeding, and hematological cancer.

Morbidity/function. High — chronic relapses, transfusion dependence during flares, cumulative multisystem immunopathology, and immunosuppression-related complications. Disease-specific QoL instruments were not identified (gap).

Complications. Recurrent/severe infections (major driver of mortality), thrombosis (including reports of Buerger's disease and spontaneous echocardiographic contrast), hematological malignancy, and progression to SLE.

Prognostic factors. Independent predictors of mortality: number of second-line treatments and severe/recurrent infections (F003). Secondary etiology predicts markedly worse survival (F006). ANA positivity + age >10 + high titer predicts SLE progression (F005). Immunopathological manifestations reduce splenectomy benefit.

12. Treatment

Pharmacogenomics/personalized medicine. Genotype-directed therapy is a defining trend: abatacept for CTLA4/LRBA, sirolimus/leniolisib for ALPS/APDS, JAK inhibitors for interferon/JAK-STAT–driven dysregulation. Treatment strategy: escalate from steroids/IVIG → rituximab/sirolimus → genotype-targeted agents; reserve splenectomy for selected cases; support with transfusion, infection prophylaxis, and thrombosis awareness.

13. Prevention

Primary prevention: none (no modifiable cause). Secondary prevention: early recognition of coexistent cytopenias and prompt immunosuppression; early IEI genetic diagnosis enables targeted therapy and family counseling. Tertiary prevention: infection prophylaxis (vaccination, especially before/after splenectomy — encapsulated-organism vaccines; antibiotic prophylaxis post-splenectomy), thrombosis vigilance, monitoring for SLE progression and malignancy, and surveillance for accruing immunopathological manifestations. Genetic counseling is indicated when a monogenic IEI is found (variable inheritance patterns). No immunization prevents ES itself.

14. Other Species / Natural Disease

Taxonomy. Naturally occurring ES is well documented in the domestic dog (Canis lupus familiaris, NCBI:txid9615) — concurrent immune-mediated hemolytic anemia and immune-mediated thrombocytopenia (F009). Reported breeds: Rottweiler, Miniature Schnauzer, Dachshund. Canine cases are DAT-positive and glucocorticoid/immunosuppressant-responsive, and can be complicated by thrombosis and opportunistic infection during immunosuppression — closely paralleling human disease.

Orthologous genes. FAS, FASLG, CTLA4, LRBA, PIK3CD orthologs are conserved across mammals. Comparative biology: the FAS apoptosis mechanism is evolutionarily conserved, underpinning both canine natural disease and rodent models. Zoonotic potential: none (autoimmune, non-transmissible).

15. Model Organisms

Model type. Mammalian (mouse) genetic models of the FAS pathway recapitulate ALPS-type ES (F009). Specific systems: MRL/lpr (Fas^lpr) mouse (Fas loss of function) and gld (Faslg) mouse (FAS ligand defect) — both develop lymphoproliferation, TCRαβ+ DNT-cell accumulation, autoantibodies, and autoimmune cytopenias.

Applications. These models study the apoptosis-defect mechanism, DNT-cell biology, and therapeutics — e.g., leniolisib reduced lymphoproliferative disease in murine ALPS (F009), validating targeted therapy translation. Limitations: lpr/gld mice best model the ALPS/FAS subtype and background-dependent lupus-like autoimmunity; they do not capture the full heterogeneity of human ES (CTLA4, LRBA, APDS, NFKB1, SASH3, secondary ES). Resources: MGI, IMSR for Fas/Faslg alleles.

Mechanistic Model / Interpretation

Evans syndrome should be conceptualized as a shared downstream phenotype produced by many upstream lesions of immune tolerance. The unifying "trunk" is autoantibody-mediated, Fc-receptor/complement-driven splenic destruction of red cells and platelets. The "roots" are diverse: defective apoptosis (ALPS/FAS pathway), failed Treg checkpoints (CTLA4/LRBA), signaling hyperactivation (PIK3CD/APDS), transcriptional haploinsufficiency (NFKB1), adaptor loss (SASH3), or a structural syndrome (22q11.2/pDGS) — and, in a large fraction, no identifiable single gene (polygenic/multifactorial autoimmunity), or a secondary driver (SLE, lymphoma).

This model explains the clinical behavior: because the root cause is systemic immune dysregulation, ES is rarely "just" a blood disease — it tends to recruit additional autoimmune and lymphoproliferative manifestations over time (74% by age 20), progresses to SLE in high-risk ANA-positive children, relapses despite treatment, and kills primarily through infection (reflecting the immunodeficiency side of the dysregulation) and bleeding. It also explains why therapy is migrating from broad immunosuppression toward mechanism-matched targeted agents (abatacept, sirolimus/leniolisib, JAK inhibitors), which requires molecular diagnosis via genomic sequencing.

Evidence Base

Limitations and Knowledge Gaps

• No dedicated OMIM/ICD entry: ES is coded by its components; identifiers are inherited from underlying IEIs, complicating standardized annotation.
• Adult vs pediatric divergence: monogenic IEI yield is high in children but low in adults; conclusions from pediatric cohorts may not transfer to adult-onset disease.
• QoL data absent: no ES-specific EQ-5D/SF-36/PROMIS evidence was identified.
• Epigenetics unstudied: no ES-specific methylation/histone or single-cell/spatial multi-omics signature was found in the reviewed literature.
• Primary/idiopathic ES mechanism inferred: for the large fraction lacking an identified gene, the tolerance-defect chain is extrapolated from monogenic cases, not directly demonstrated.
• Two citation snippets were flagged "mismatch" in the knowledge state (37008642 41608120 — title-based); their claims (canine ES; murine ALPS + leniolisib) are corroborated by companion verified citations but should be re-verified against full text.
• Treatment evidence is largely from cohorts, single-arm trials, and case reports; randomized comparative data are scarce given rarity.

Proposed Follow-up Experiments / Actions

1. Systematic genomic testing study stratified by age of onset to define IEI yield thresholds and cost-effectiveness of WES/WGS in adult vs pediatric ES.
2. Prospective biomarker panel (DNT cells, sFASL, ANA titer, IL-10, immunoglobulins) to build a validated risk-stratification model for SLE progression, malignancy, and mortality.
3. Genotype-stratified therapeutic trials matching targeted agents to mechanism (abatacept for CTLA4/LRBA; leniolisib for APDS; JAK inhibitors for interferonopathy-like dysregulation).
4. Single-cell and spatial immune profiling of spleen/marrow/blood to map the autoreactive B-cell and DNT-cell compartments and identify novel targets.
5. ES-specific QoL/PRO instrument development and longitudinal capture within existing registries (OBS'CEREVANCE, Danish).
6. Comparative canine studies leveraging naturally occurring canine ES as a translational large-animal model for therapeutics.

Report compiled from 9 confirmed findings and 34 reviewed papers across 5 investigation iterations. Evidence source types: predominantly human clinical (national cohorts, registries, case series), with model-organism (Fas^lpr/gld mouse) and natural-disease (canine) corroboration.